White Button Mushroom Extract for Breast Cancer Risk Reduction
Recruiting in Palo Alto (17 mi)
Overseen byLisa D Yee
Age: 18+
Sex: Female
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: City of Hope Medical Center
Must not be taking: Anticoagulants, Hormone modifiers, Immunosuppressants, others
Disqualifiers: Active malignancy, Chemotherapy, Bleeding tendency, others
No Placebo Group
Trial Summary
What is the purpose of this trial?
This trial is testing if eating white button mushrooms every day can help improve health in obese postmenopausal women at high risk of breast cancer. The mushrooms might help by making immune cells work better and reducing long-term inflammation. Researchers hope this could lower the risk of breast cancer and improve overall health.
Will I have to stop taking my current medications?
The trial requires that you stop using hormone-modifying medications, immunosuppressants, and certain herbal or dietary supplements containing mushrooms at least 3 months before joining. You also cannot be on full-dose aspirin, NSAIDs, or anticoagulants like Coumadin. If you're on any of these, you may need to stop them to participate.
What data supports the effectiveness of the treatment White Button Mushroom Extract for reducing breast cancer risk?
Research shows that white button mushrooms (Agaricus bisporus) have compounds that can help fight breast cancer by boosting the immune system and directly inhibiting cancer cell growth. Studies on rats and human cancer cells suggest these mushrooms may reduce tumor growth and have protective effects against breast cancer.12345
Is White Button Mushroom Extract safe for humans?
Some studies in mice and rats have shown that consuming Agaricus bisporus (White Button Mushroom) can lead to tumor development in various organs, but these results are not consistent across all studies. One study in rats did not find a significant difference in tumor incidence between those fed the mushroom and those not, suggesting no clear evidence of carcinogenicity. However, these findings are based on animal studies, and more research is needed to determine safety in humans.24678
How does white button mushroom extract differ from other breast cancer treatments?
Eligibility Criteria
This trial is for postmenopausal women with a high BMI (>=30 kg/m^2), at increased risk of breast cancer due to factors like genetic mutations (BRCA1/2, p53), family history, or previous diagnoses of certain breast conditions. Participants must be over 21 years old, have had no recent mushroom supplements, and not be on hormone therapies or other treatments that could interfere.Inclusion Criteria
I finished any previous cancer treatments over 6 months ago and stopped taking mushroom supplements within the last 3 months.
Your total white blood cell count is less than 3500 per cubic millimeter.
I am a postmenopausal woman aged 21 or older.
See 21 more
Exclusion Criteria
You are allergic to substances similar to WBM.
I have a history of bleeding easily or am currently using blood thinners.
I do not have any serious illnesses or social situations that would stop me from following the study's requirements.
See 10 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive white button mushroom orally daily for 3 months
12 weeks
Regular visits for monitoring
Follow-up
Participants are monitored for safety and effectiveness after treatment
4 weeks
Treatment Details
Interventions
- White Button Mushroom Extract (Cancer Vaccine)
Trial OverviewResearchers are testing the effects of white button mushroom extract on inflammation and immune function in obese postmenopausal women at high risk for breast cancer. The study involves taking the supplement and monitoring changes through questionnaires and blood tests to see if it might reduce body fat or cancer risk.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Prevention (white button mushroom)Experimental Treatment2 Interventions
Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
City of Hope Medical CenterDuarte, CA
Loading ...
Who Is Running the Clinical Trial?
City of Hope Medical CenterLead Sponsor
National Cancer Institute (NCI)Collaborator
References
Fighting secondary triple-negative breast cancer in cerebellum: A powerful aid from a medicinal mushrooms blend. [2023]Breast cancer (BC) is the second most common cause of brain metastasis onset in patients, with the cerebellum accounting for the 33% of cases. In the current study, using a 4T1 triple-negative mouse BC model, we revealed that an orally administered medicinal mushrooms (MM) blend, rich in β-glucans, played a direct and specific anti-cancer action on cerebellar metastases, also bettering locomotor performances. The neuroprotective effect of the MM blend plays through (i) a direct and specific inhibition of cerebellar metastatization pattern typical of TNBC (with an induced reduction of about 50% of metastases density) and (ii) the regulation of apoptosis and proliferation-related genes, as suggested by expression changes of specific molecular markers, i.e. PCNA, p53, Bcl2, BAX, CASP9, CASP3, Hsp70 and AIF. Therefore, inhibiting the metastatization process, triggering a significant apoptosis increase, and lessening cell proliferation, this MM supplement, employed as adjuvant treatment in association with conventional therapy, could represent a promising approach, in the field of Integrative Oncology, for patients' management in both prevention and treatment of brain metastases from BC.
Evaluating the therapeutic potential of white button mushroom (Agaricus bisporus) against DMBA-induced breast cancer in Sprague Dawley rats. [2022]The current research work was designed to investigate the protective effects of white button mushroom (Agaricus bisporus) against 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer. Breast cancer was induced in rats by the administration of a single dose of 50 mg/kg DMBA via gavage. The rats were divided into four groups: G1 (negative control group), G2 (positive control group), G3 (rats receiving mushroom extract), and G4 (rats administered with doxorubicin). The mushroom extract significantly (p
Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer. [2023]Edible/medicinal mushrooms have been traditionally used in Asian countries either in the cuisine or as dietary supplements and nutraceuticals. In recent decades, they have aroused increasing attention in Europe as well, due to their health and nutritional benefits. In particular, among the different pharmacological activities reported (antibacterial, anti-inflammatory, antioxidative, antiviral, immunomodulating, antidiabetic, etc.), edible/medicinal mushrooms have been shown to exert in vitro and in vivo anticancer effects on several kinds of tumors, including breast cancer. In this article, we reviewed mushrooms showing antineoplastic activity again breast cancer cells, especially focusing on the possible bioactive compounds involved and their mechanisms of action. In particular, the following mushrooms have been considered: Agaricus bisporus, Antrodia cinnamomea, Cordyceps sinensis, Cordyceps militaris, Coriolus versicolor, Ganoderma lucidum, Grifola frondosa, Lentinula edodes, and Pleurotus ostreatus. We also report insights into the relationship between dietary consumption of edible mushrooms and breast cancer risk, and the results of clinical studies and meta-analyses focusing on the effects of fungal extracts on breast cancer patients.
Macrophage immunomodulating and antitumor activities of polysaccharides isolated from Agaricus bisporus white button mushrooms. [2016]Agaricus bisporus white button mushroom (WBM) is widely consumed in most countries for its culinary properties. Recently, its dietary intake has been shown to protect against breast cancer. Mushroom polysaccharides are known for their immunomodulating and antitumor properties; however, little is known regarding the properties of A. bisporus polysaccharides. Using size-exclusion chromatography to fractionate the crude extract of A. bisporus, two polysaccharide fractions (designated as ABP-1 and ABP-2) were obtained. The estimated molecular masses of ABP-1 and ABP-2 were 2,000 kDa and 40-70 kDa, respectively, and their sugar compositions consisted mainly of glucose, mannose, xylose, and fructose. Analysis of the effects of the polysaccharides on murine macrophages demonstrated that both fractions stimulated the production of nitric oxide, interleukin-6, and tumor necrosis factor-α. Modulation of macrophage function by A. bisporus polysaccharides was mediated in part through activation of nuclear factor-κB with the production p50/105 heterodimers. Both ABP-1 and ABP-2 had the ability to inhibit the growth of human breast cancer MCF-7 cells but had little effect on the growth of human colon, prostate, gastric cancer, and murine Sarcoma 180 cells as assessed by a tetrazolium dye [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]-based assay. However, when murine Sarcoma 180 cells exposed to ABP-1 or ABP-2 were implanted subcutaneously into mice, a reduction in tumor growth was observed compared with that observed in control mice. Taken together, our data provide a molecular basis to explain in part the reported beneficial therapeutic effects of A. bisporus WBM intake and suggest that macrophages likely contribute to the antitumor effects of Agaricus polysaccharides.
In vitro effects on proliferation, apoptosis and colony inhibition in ER-dependent and ER-independent human breast cancer cells by selected mushroom species. [2015]Breast cancer is the most commonly diagnosed cancer among women in Western countries. Currently, there is no effective therapy for malignant estrogen-independent breast cancer. We have screened 38 species of edible mushroom on human estrogen-receptor positive (MCF-7) and estrogen-receptor negative (MDA-MB-231, BT-20) breast cancer cells to select potential agents with broad-spectrum antitumor activity against breast cancer cells. Water-based extracts of three mushroom species, Coprinellus sp., Coprinus comatus, Flammulina velutipes (CME, CCE and FVE, respectively), were identified as novel anti-breast cancer agents. The anti-tumor activities include: 1) marked growth inhibition of both ER+ and ER- breast cancer cells; 2) induction of rapid apoptosis on both ER+ and ER- cells; 3) significant inhibition of MCF-7 tumor colony formation in vitro. The antiproliferative and cytotoxic activities of the three mushroom extracts were dose-dependent, regardless of the hormone receptor status of the cancer cells. The degree of produced cytotoxicity on ER- breast cancer cells was very high, while the IC50 of mushroom extract CME was found to be as low as 40 microg/ml on MDA-MB-231 cells and the IC50 of mushroom extract FVE was only 30 microg/ml on BT-20 cells. More interestingly, mushroom extracts CME and FVE induced an exceptionally rapid apoptosis on MCF-7 and MDA-MB-231 detected by Annexin V-FITC within 2 h of treatment and DNA fragment end-labeling assay (TUNEL) in 5 h of treatment. Anchorage-independent growth assays indicated that the MCF-7 tumor colony formation rate was reduced by 60% in CCE- and CME-treated cells and nearly completely inhibited (99%) by FVE treatment. These results suggest that mushroom species Coprinus comatus, Coprinellus sp. and Flammulina velutipes contain potent antitumor compounds for breast cancer. Our finding is important due to the lack of chemotherapeutic and chemopreventive agents for ER- human breast cancer.
Carcinogenesis studies with the lyophilized mushroom Agaricus bisporus in mice. [2007]Continuous administration of 10, 5, and 2.5% lyophilized Agaricus bisporus (AB) mushroom in the diet of six-week-old, randomly bred Swiss mice for life induced tumors in the lungs, forestomach, glandular stomach, and ovaries in certain groups. Some of the tumor incidences were found to be statistically significant, although no dose-response relationship was established. Histopathologically, the neoplasms were classified as adenomas and adenocarcinomas of lungs, glandular stomach, and ovaries and squamous cell papillomas and carcinomas of the forestomach. AB given in both raw and baked forms induced tumors in the same species in earlier experiments. Since this fungus is consumed in lyophilized form to a certain degree in the United States, the results may carry practical significance.
Cancer induction in mice by feeding of the uncooked cultivated mushroom of commerce Agaricus bisporus. [2007]The cultivated mushroom of commerce in the Western hemisphere, Agaricus bisporus, was given p.o. to randomly bred Swiss mice for 3 days and was followed by semisynthetic diet for 4 days each week for life. The mice were 6 weeks old at the beginning of the experiment. As a result of treatment, tumors were induced in the bone, forestomach, liver, and lungs in the following incidences: 16, 38, 8, and 40% in females and 16, 28, 12, and 62% in males, respectively. The corresponding tumor incidences in the untreated controls were 0, 0, 0, and 26% in females and 0, 4, 2, and 34% in males, respectively. Histopathologically, the tumors were classified as osteomas and osteosarcomas, squamous cell papillomas and carcinomas of forestomach, benign hepatomas, and adenomas and adenocarcinomas of lungs. The investigation thus proves the carcinogenicity of uncooked Agaricus bisporus.
Carcinogenicity examination of Agaricus bisporus, edible mushroom, in rats. [2019]Carcinogenicity of Agaricus bisporus, the edible mushroom, was studied in rats. Female Charles River Sprague - Dawley rats (CD rats) were given a diet containing a 30% dry powder of A. bisporus for 500 days until the termination of the experiment. A control group was given a basal diet without A. bisporus. The rats in the experimental group had mammary tumor, thymoma, adrenal adenoma and pituitary adenoma. However, there was no significant difference in the incidence of these tumors between the experimental group and control group. No carcinogenic activity of A. bisporus was observed in this experiment.
White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft. [2022]White button mushroom (WBM) (Agaricus bisporus) is a potential prostate cancer (PCa) chemo-preventative and therapeutic agent. Our clinical phase І trial of WBM powder in patients with biochemically recurrent PCa indicated that WBM intake reduced the circulating levels of prostate-specific antigen (PSA). We hypothesized that WBM exerts its effects on PCa through the androgen receptor (AR) signaling axis. Therefore, we conducted a reverse translational study with androgen-dependent PCa cell lines (LNCaP and VCaP) and patient-derived-xenografts (PDX) from a prostate tumor (TM00298). In both LNCaP and VCaP cells, western blots and qRT-PCR assays indicated that WBM extract (6-30 mg/mL) suppressed DHT-induced PSA expression and cell proliferation in a dose-dependent manner. Immunofluorescence analysis of AR revealed that WBM extract interrupted the AR nuclear-cytoplasmic distribution. PSA promotor-luciferase assay suggested that WBM extract inhibited DHT-induced luciferase activity. RNA-Seq on WBM-treated LNCaP cells confirmed that WBM treatment suppressed the androgen response pathways and cell-cycle control pathways. Our PDX showed that oral intake of WBM extract (200 mg/kg/d) suppressed tumor growth and decreased PSA levels in both tumors and serum. In the present study, we also identified a conjugated linoleic acid isomer (CLA-9Z11E) as a strong AR antagonist by performing LanthaScreen TR-FRET AR Coactivator Interaction Assays. The inhibitory effect of CLA-9Z11E (IC50: 350 nM) was nearly two times stronger than the known AR antagonist, cyproterone acetate (IC50: 672 nM). The information gained from this study improves the overall understanding of how WBM may contribute to the prevention and treatment of PCa.